TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
InhaleRx Limited ( (AU:IRX) ) just unveiled an announcement.
InhaleRx Limited has announced the issuance of unquoted equity securities, including 2,324,926 performance rights in lieu of director fees and 1,000,000 unlisted options with an exercise price of $0.12 expiring on July 7, 2028. This strategic move is part of previously announced transactions and is not intended to be quoted on the ASX, potentially impacting the company’s financial structure and aligning director incentives with long-term company performance.
More about InhaleRx Limited
InhaleRx Limited operates in the pharmaceutical industry, focusing on the development and commercialization of inhalation-based drug delivery systems. The company is dedicated to providing innovative solutions for respiratory health and other therapeutic areas, leveraging cutting-edge technology to enhance patient outcomes.
Average Trading Volume: 318,939
Technical Sentiment Signal: Buy
Current Market Cap: A$8.54M
For detailed information about IRX stock, go to TipRanks’ Stock Analysis page.